IOVANCE BIOTHERAPEUTICS, INC. Costs and Expenses
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Costs and Expenses of $151.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. costs and expenses for the quarter ending 2026-06-30 was $151.22M, a 12.96% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. costs and expenses for the quarter ending 2026-03-31 was $152.47M, a 10.60% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. costs and expenses for the quarter ending 2025-12-31 was $160.23M, a 0.02% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. costs and expenses for the quarter ending 2025-09-30 was $162.36M, a 9.98% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. costs and expenses for fiscal 2025 was $666.86M, a 19.22% increase from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. costs and expenses for fiscal 2024 was $559.35M, a 21.14% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. costs and expenses for fiscal 2023 was $461.75M, a 15.76% increase from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. costs and expenses for fiscal 2022 was $398.88M, a 16.39% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $151.22M 10-Q · filed 2026-08-06 | $303.69M 10-Q · filed 2026-08-06 | $463.92M derived: sum of 3 quarters · filed 2026-08-06 | $626.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $152.47M 10-Q · filed 2026-05-07 | $312.70M derived: sum of 2 quarters · filed 2026-05-07 | $475.06M derived: sum of 3 quarters · filed 2026-05-07 | $648.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $160.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $322.59M derived: sum of 2 quarters · filed 2026-02-24 | $496.31M derived: sum of 3 quarters · filed 2026-08-06 | $666.86M 10-K · filed 2026-02-24 |
| 2025-09-30 | $162.36M 10-Q · filed 2025-11-06 | $336.08M derived: sum of 2 quarters · filed 2026-08-06 | $506.63M 10-Q · filed 2025-11-06 | $666.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $173.73M 10-Q · filed 2026-08-06 | $344.27M 10-Q · filed 2026-08-06 | $504.54M derived: sum of 3 quarters · filed 2026-08-06 | $652.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $170.54M 10-Q · filed 2026-05-07 | $330.81M derived: sum of 2 quarters · filed 2026-05-07 | $478.44M derived: sum of 3 quarters · filed 2026-05-07 | $611.46M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $160.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $307.89M derived: sum of 2 quarters · filed 2026-02-24 | $440.91M derived: sum of 3 quarters · filed 2026-02-24 | $559.35M 10-K · filed 2026-02-24 |
| 2024-09-30 | $147.62M 10-Q · filed 2025-11-06 | $280.64M derived: sum of 2 quarters · filed 2025-11-06 | $399.08M 10-Q · filed 2025-11-06 | $520.82M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $133.02M 10-Q · filed 2025-08-07 | $251.46M 10-Q · filed 2025-08-07 | $373.19M derived: sum of 3 quarters · filed 2026-02-24 | $492.02M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $118.44M 10-Q · filed 2025-05-08 | $240.18M derived: sum of 2 quarters · filed 2026-02-24 | $359.00M derived: sum of 3 quarters · filed 2026-02-24 | $469.33M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $121.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $240.57M derived: sum of 2 quarters · filed 2026-02-24 | $350.89M derived: sum of 3 quarters · filed 2026-02-24 | $461.75M 10-K · filed 2026-02-24 |
| 2023-09-30 | $118.83M 10-Q · filed 2024-11-07 | $229.15M derived: sum of 2 quarters · filed 2024-11-07 | $340.01M 10-Q · filed 2024-11-07 | $447.05M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $110.32M 10-Q · filed 2024-08-08 | $221.18M 10-Q · filed 2024-08-08 | $328.22M derived: sum of 3 quarters · filed 2025-02-27 | $428.61M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $110.86M 10-Q · filed 2024-05-09 | $217.89M derived: sum of 2 quarters · filed 2025-02-27 | $318.29M derived: sum of 3 quarters · filed 2025-02-27 | $418.02M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $107.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $207.43M derived: sum of 2 quarters · filed 2025-02-27 | $307.17M derived: sum of 3 quarters · filed 2025-02-27 | $398.88M 10-K · filed 2025-02-27 |
| 2022-09-30 | $100.39M 10-Q · filed 2023-11-07 | $200.13M derived: sum of 2 quarters · filed 2023-11-07 | $291.84M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $99.73M 10-Q · filed 2023-08-08 | $191.45M 10-Q · filed 2023-08-08 | ||
| 2021-12-31 | $342.70M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |